MARKET

PROK

PROK

ProKidney
NASDAQ
2.530
-0.040
-1.56%
After Hours: 2.510 -0.02 -0.79% 19:00 12/26 EST
OPEN
2.560
PREV CLOSE
2.570
HIGH
2.560
LOW
2.470
VOLUME
693.12K
TURNOVER
--
52 WEEK HIGH
7.13
52 WEEK LOW
0.4603
MARKET CAP
761.11M
P/E (TTM)
-4.6482
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PROK last week (1215-1219)?
Weekly Report · 6d ago
ProKidney (PROK) Price Target Increased by 15.10% to 6.85
NASDAQ · 12/21 22:46
ProKidney Initiated at Buy by HC Wainwright & Co.
Dow Jones · 12/16 12:13
ProKidney Price Target Announced at $12.00/Share by HC Wainwright & Co.
Dow Jones · 12/16 12:13
This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Benzinga · 12/16 12:10
HC Wainwright & Co. Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $12
Benzinga · 12/16 12:03
ProKidney initiated with a Buy at H.C. Wainwright
TipRanks · 12/16 11:10
PROKIDNEY CORP. <PROK.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING
Reuters · 12/16 11:09
More
About PROK
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

Webull offers ProKidney Corp stock information, including NASDAQ: PROK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PROK stock methods without spending real money on the virtual paper trading platform.